A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment

[1]  F W MULSOW,et al.  Cancer incidence and mortality , 2019, Health at a Glance: Europe.

[2]  E. Abdalla.  Resection of Colorectal Liver Metastases , 2011, Journal of Gastrointestinal Surgery.

[3]  Byung Soh Min,et al.  Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. , 2009, American journal of surgery.

[4]  F. Kabbinavar,et al.  Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk , 2008, Oncology.

[5]  E. Berber,et al.  Resection Versus Laparoscopic Radiofrequency Thermal Ablation Of Solitary Colorectal Liver Metastasis , 2008, Journal of Gastrointestinal Surgery.

[6]  J. Vauthey,et al.  Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  G. Gandini,et al.  Radiofrequency Ablation of Colorectal Liver Metastases: Small Size Favorably Predicts Technique Effectiveness and Survival , 2008, CardioVascular and Interventional Radiology.

[8]  Thomas Gruenberger,et al.  Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Lévi,et al.  Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Thomas Gruenberger,et al.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.

[11]  P. Tekkis,et al.  Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer: A Multifactorial Model of 929 Patients , 2008, Annals of surgery.

[12]  L. Ellis,et al.  Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases , 2007, Cancer.

[13]  E. Berber,et al.  Survival After Radiofrequency Ablation of Colorectal Liver Metastases: 10-Year Experience , 2007, Annals of surgery.

[14]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Serrano,et al.  Surgical Resection of Colorectal Liver Metastases in Patients with Expanded Indications: A Single-Center Experience with 501 Patients , 2007, Diseases of the colon and rectum.

[16]  J. Bosset,et al.  Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Ychou,et al.  Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. , 2006, European journal of cancer.

[18]  T. Pawlik,et al.  Solitary colorectal liver metastasis: resection determines outcome. , 2006, Archives of surgery.

[19]  J. Berlin,et al.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab , 2005, Journal of surgical oncology.

[20]  Guy Marchal,et al.  Local Recurrence After Hepatic Radiofrequency Coagulation: Multivariate Meta-Analysis and Review of Contributing Factors , 2005, Annals of surgery.

[21]  J. Berlin,et al.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Ferlay,et al.  Cancer incidence and mortality in Europe, 2004. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  W. Lees,et al.  Radio-frequency ablation of colorectal liver metastases in 167 patients , 2004, European Radiology.

[24]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[25]  Kenneth Hess,et al.  Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases , 2004, Annals of surgery.

[26]  L. Roncucci,et al.  Trend of incidence, subsite distribution and staging of colorectal neoplasms in the 15-year experience of a specialised cancer registry. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  R. Schilsky,et al.  Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials , 2004, British Journal of Cancer.

[28]  Napoleone Ferrara,et al.  VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.

[29]  Michael A. Choti,et al.  Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases , 2002, Annals of surgery.

[30]  S. Lipsitz,et al.  Abstracts reprinted from Journal of Clinical Oncology , 2002, Annals of Surgical Oncology.

[31]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[32]  N. Ferrara.  Role of vascular endothelial growth factor in regulation of physiological angiogenesis. , 2001, American journal of physiology. Cell physiology.

[33]  G. Neufeld,et al.  The contribution of proangiogenic factors to the progression of malignant disease: role of vascular endothelial growth factor and its receptors. , 2001, Surgical oncology clinics of North America.

[34]  M. Shibuya.  Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. , 2001, Cell structure and function.

[35]  I. B. Borel Rinkes,et al.  Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. , 2000, Cancer research.

[36]  M. Borner.  Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer--too good to be true? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  E. Raymond,et al.  Oxaliplatin: a review of preclinical and clinical studies. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  H. Ishitsuka,et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.

[39]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Jeekel,et al.  Tumour growth stimulation after partial hepatectomy can be reduced by treatment with tumour necrosis factor α , 1995, The British journal of surgery.

[41]  B. Nordlinger,et al.  Dormant liver metastases: an experimental study , 1992, The British journal of surgery.

[42]  B. Cady,et al.  Elective hepatic resection. , 1979, American journal of surgery.

[43]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[44]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[45]  S. Bengmark,et al.  Angiography of the regenerating human liver after extensive resection. , 1969, Surgery.

[46]  S Bengmark,et al.  The natural history of primary and secondary malignant tumors of the liver I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy , 1969, Cancer.

[47]  F. R. Watson,et al.  Factors influencing survival in patients with untreated hepatic metastases. , 1968, Surgery, gynecology & obstetrics.

[48]  W. McDermott,et al.  Elective hepatic resection. , 1966, American journal of surgery.

[49]  J. Hallgrímsson,et al.  Multiple Adenoma (Hamartoma) of the Liver Treated by Subtotal (90%) Resection: Morphological and Functional Studies of Regeneration , 1964 .

[50]  Peter Boyle,et al.  Cancer incidence and mortality in Europe , 2005, Sozial- und Präventivmedizin.

[51]  J. Fleshman,et al.  Liver resection for colorectal metastases. , 2004, Annals of the Royal College of Surgeons of England.

[52]  T. Pawlik,et al.  Combined Resection and Radiofrequency Ablation for Advanced Hepatic Malignancies: Results in 172 Patients , 2003, Annals of Surgical Oncology.

[53]  K. Blesch,et al.  Clinical Pharmacokinetics of Capecitabine , 2001, Clinical pharmacokinetics.

[54]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[55]  N. Ferrara,et al.  Vascular endothelial growth factor and the regulation of angiogenesis. , 2000, Recent progress in hormone research.

[56]  P. Sugarbaker.  Metastatic inefficiency: The scientific basis for resection of liver metastases from colorectal cancer , 1993, Journal of surgical oncology. Supplement.

[57]  S Bengmark,et al.  The natural history of primary and secondary malignant tumors of the liver . II. The prognosis for patients with hepatic metastases from gastric carcinoma verified by laparotomy and postmortem examination. , 1969, Digestion.

[58]  J. Hallgrímsson,et al.  MULTIPLE ADENOMA (HAMARTOMA) OF THE LIVER TREATED BY SUBTOTAL (90 PERCENT) RESECTION: MORPHOLOGICAL AND FUNCTIONAL STUDIES OF REGENERATION. , 1964, Annals of surgery.